Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine Inc. (MNMD) is a clinical-stage biotech company pioneering research into psychedelic-inspired therapies for mental health disorders. This dedicated news hub provides investors and researchers with timely updates on MNMD's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases detailing clinical trial progress, partnership announcements with leading research institutions, and analyses of the company's novel approaches to treating conditions like addiction and depression. Our curated collection ensures you stay informed about MNMD's work developing therapies that target neuroplasticity through compounds such as LSD-analogs and psilocybin derivatives.
Key updates include Phase 2 trial results, intellectual property developments, executive leadership changes, and presentations at major medical conferences. All content is sourced from verified channels to maintain compliance with financial disclosure standards.
Bookmark this page for streamlined access to MNMD's evolving story in psychedelic medicine. Check regularly for critical updates about FDA-regulated research programs and breakthrough therapy designation tracking within this emerging biopharmaceutical sector.
MindMed (Nasdaq: MNMD), a psychedelic medicine biotech firm, has published the first pharmacogenetic data on LSD, which may help personalize dosing for patients. The study analyzed data from four Phase 1 trials conducted at the University Hospital Basel, revealing that genetic factors, especially CYP2D6 variations, significantly influence LSD metabolism and its psychological effects. The findings suggest that metabolic testing can inform individual LSD dosing. This research is a critical step in developing LSD as a medication, emphasizing the need for tailored patient treatment.
MindMed (NASDAQ: MNMD) has signed a Memorandum of Understanding (MOU) with Nextage Therapeutics (TASE: NXTG) to collaboratively develop a drug delivery system using Nextage's Brain Targeting Liposome System (BTLS) for ibogaine derivatives, including noribogaine. This partnership aims to optimize the efficacy of psychedelics while minimizing side effects, particularly for opioid addiction treatments. Both companies will share development costs and jointly own resulting intellectual property. If successful, this initiative could lead to significant advancements in psychedelic medicine.
MindMed (Nasdaq: MNMD) announced the approval of its first clinical trial evaluating mescaline's effects and its interaction with the serotonin 5-HT2A receptor. Conducted at the University Hospital Basel in Switzerland, the trial will begin this month. The study aims to provide modern scientific data on mescaline, which has historical significance yet lacks contemporary research. It will explore the dosing, subjective effects, and mechanisms of action of mescaline through a rigorous double-blind, placebo-controlled design. The results may lead to further investigations into mescaline's therapeutic potential.
On May 18, 2021, Mind Medicine (MindMed) (NASDAQ: MNMD) announced a partnership with The Chopra Foundation to enhance public awareness regarding psychedelic therapies for mental health. The collaboration aims to conduct research on psychedelic psychotherapy and its benefits for mental wellbeing, integrating digital therapeutics into treatment. The CEO, J.R. Rahn, emphasized the urgency for innovative mental health solutions, especially during Mental Health Awareness Month. This partnership may pave the way for new treatment modalities amidst a rising mental health crisis in the U.S.
MindMed has finalized its clinical development strategy for LSD, targeting Generalized Anxiety Disorder (GAD) as its initial indication. Following positive FDA feedback, the company plans to submit an Investigational New Drug (IND) application in Q3 2021, with a Phase 2b clinical trial expected to launch in Q4 2021. This trial will involve approximately 200 patients and aim to assess the efficacy of LSD in alleviating anxiety symptoms. The initiative marks a significant step in advancing psychedelic therapy for mental health issues, particularly since innovation in GAD treatment has lagged for decades.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has appointed Dr. Sarah Y. Vinson as a director and member of the audit committee, effective immediately. Dr. Vinson is a triple board-certified psychiatrist with significant experience in child and adolescent psychiatry, and she aims to drive innovation in mental health treatments. Her appointment is part of a strategy to enhance board independence and expertise. Dr. Vinson will be nominated for election at the upcoming shareholder meeting on May 27, 2021. This appointment highlights MindMed's commitment to expanding its leadership in the psychedelic medicine sector.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported financial results for Q1 2021, with total assets of $201 million and a cash balance of $160 million. The company incurred a net loss of $14 million for the quarter, with a cash burn of $10 million. Key business developments include the acquisition of HealthMode, clinical trials for MDMA and LSD, and significant financing efforts totaling $73 million USD and $15.4 million USD. Management will discuss these results in an earnings call on May 17, 2021.
MindMed (NASDAQ: MNMD) has appointed Peter Mack, PhD, as Vice President of Pharmaceutical Development. He will oversee product development across MindMed's portfolio, including LSD and ibogaine derivative 18-MC. Previously, Peter held a senior role at AstraZeneca, contributing to inhalation therapies for respiratory diseases. His dual PhD from Harvard and MIT positions him to strengthen MindMed's development pipeline, focused on psychedelic-inspired medicines for addiction and mental health disorders. CEO J.R. Rahn expressed excitement over Mack's addition to the team.
On May 5, 2021, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the launch of Project Angie to advance psychedelics, particularly LSD, for treating pain conditions. The company will initiate a Phase 2a Proof of Concept study, submitting a pre-IND briefing to the FDA in the latter half of 2021. With the global analgesics market projected to grow by over $31 billion by 2030, MindMed seeks to innovate within the pain treatment sector. Preliminary studies indicate psychedelics may offer a novel treatment mechanism for pain relief.
MindMed (Nasdaq: MNMD) has officially commenced trading on The Nasdaq Capital Market as of April 27, 2021. The company's shares previously traded on the OTCQB under the symbol MMEDF and will now be traded under the symbol MNMD. MindMed will also retain its listing on the Neo Exchange under the symbol MMED. The announcement includes a live bell ringing ceremony, highlighting the significance of this transition for the company, which focuses on developing psychedelic-inspired therapies for addiction and mental health.
FAQ
What is the current stock price of Mind Medicine (MNMD)?
What is the market cap of Mind Medicine (MNMD)?
